Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first-line intensified treatment of pediatric patients with high-risk acute lymphoblastic leukemia in CoALL08-09 trial.
Mezger K, Ebert S, Muhle HE, Stadt UZ, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Zimmermann M, Horstmann MA, Escherich G. Mezger K, et al. Among authors: faber j. Pediatr Blood Cancer. 2022 Dec;69(12):e29997. doi: 10.1002/pbc.29997. Epub 2022 Sep 21. Pediatr Blood Cancer. 2022. PMID: 36129234
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
Creutzig U, Dworzak MN, Bochennek K, Faber J, Flotho C, Graf N, Kontny U, Rossig C, Schmid I, von Stackelberg A, Mueller JE, von Neuhoff C, Reinhardt D, von Neuhoff N. Creutzig U, et al. Among authors: faber j. Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26461. Epub 2017 Jan 23. Pediatr Blood Cancer. 2017. PMID: 28111878
Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.
Schramm F, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Feuchtinger T, Schmid I, Beron G, Horstmann MA, Escherich G. Schramm F, et al. Among authors: faber j. Leuk Lymphoma. 2019 Jan;60(1):60-68. doi: 10.1080/10428194.2018.1473575. Epub 2018 Jul 3. Leuk Lymphoma. 2019. PMID: 29966458 Clinical Trial.
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.
Schramm F, Zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Schmid I, Feuchtinger T, Beron G, den Boer ML, Pieters R, Horstmann MA, Janka-Schaub GE, Escherich G. Schramm F, et al. Among authors: faber j. Blood Adv. 2019 Nov 26;3(22):3688-3699. doi: 10.1182/bloodadvances.2019000576. Blood Adv. 2019. PMID: 31765480 Free PMC article.
Social inequalities in the participation and activity of children and adolescents with leukemia, brain tumors, and sarcomas (SUPATEEN): a protocol for a multicenter longitudinal prospective observational study.
Roick J, Berner R, Bernig T, Erdlenbruch B, Escherich G, Faber J, Klein C, Bochennek K, Kratz C, Kühr J, Längler A, Lode HN, Metzler M, Müller H, Reinhardt D, Sauerbrey A, Schepper F, Scheurlen W, Schneider D, Schwabe GC, Richter M. Roick J, et al. Among authors: faber j. BMC Pediatr. 2020 Jan 31;20(1):48. doi: 10.1186/s12887-020-1943-3. BMC Pediatr. 2020. PMID: 32005112 Free PMC article.
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
Escherich G, Zur Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, Schmid I, Schramm F, Spohn M, Zimmermann M, Horstmann MA. Escherich G, et al. Among authors: faber j. Haematologica. 2022 May 1;107(5):1026-1033. doi: 10.3324/haematol.2021.279357. Haematologica. 2022. PMID: 34348455 Free PMC article. Clinical Trial.
A Multimodal Lifestyle Psychosocial Survivorship Program in Young Cancer Survivors: The CARE for CAYA Program-A Randomized Clinical Trial Embedded in a Longitudinal Cohort Study.
von Grundherr J, Elmers S, Koch B, Hail LA, Mann J, Escherich G, Bergelt C, Samland L, Jensen W, Vettorazzi E, Stark M, Valentini L, Baumann FT, Singer S, Reer R, Beller R, Calaminus G, Faber J, Classen CF, Gebauer J, Hilgendorf I, Koehler M, Puzik A, Salzmann N, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer AK, Bokemeyer C, Sinn M, Stein A, Dwinger S, Salchow J. von Grundherr J, et al. Among authors: faber j. JAMA Netw Open. 2024 Mar 4;7(3):e242375. doi: 10.1001/jamanetworkopen.2024.2375. JAMA Netw Open. 2024. PMID: 38526495 Free PMC article. Clinical Trial.
Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.
Rettinger E, Merker M, Salzmann-Manrique E, Kreyenberg H, Krenn T, Dürken M, Faber J, Huenecke S, Cappel C, Bremm M, Willasch A, Bakhtiar S, Jarisch A, Soerensen J, Klingebiel T, Bader P. Rettinger E, et al. Among authors: faber j. Biol Blood Marrow Transplant. 2017 Jan;23(1):87-95. doi: 10.1016/j.bbmt.2016.10.006. Epub 2016 Oct 11. Biol Blood Marrow Transplant. 2017. PMID: 27742575 Free article.
1,301 results